Drug Profile
Darigabat - Cerevel Therapeutics
Alternative Names: CVL-865; PF-06372865; PF-6372865Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Cerevel Therapeutics; Pfizer
- Class Analgesics; Antiepileptic drugs; Anxiolytics; Fluorobenzenes; Heterocyclic compounds; Imidazoles; Phenyl ethers; Pyrazines; Small molecules; Sulfones
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy; Panic disorder; Seizures
- Preclinical Anxiety disorders
- Discontinued Back pain; Generalised anxiety disorder
Most Recent Events
- 31 Jul 2023 Phase-II clinical trials in Panic disorder in USA (PO) (NCT05941442)
- 07 Jul 2023 Cerevel Therapeutics completes a phase I pharmacokinetics trial (In volunteers, In adults) in USA (PO,Tablet) (NCT05824143)
- 17 Apr 2023 Cerevel Therapeutics initiates enrolment in a phase I pharmacokinetics trial (In volunteers, In adults) in USA (PO,Tablet)(NCT05824143)